# Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors

> **NCT01283945** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut de Recherches Internationales Servier** · enrollment: 134 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** Lucitanib

## Key facts

- **NCT ID:** NCT01283945
- **Lead sponsor:** Institut de Recherches Internationales Servier
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2016-09
- **Final completion:** 2017-05-04
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2024-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01283945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01283945, "Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01283945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*